myelodysplastic syndromes (MDS) is a $3.5b market and Syntara only need to contribute 700k, more importantly it go straight into Phase 2 later this year.
This is substantially more commercialized focus and less time consuming than the previous myelofibrosis trails.
Not sure how long it'll take before the market realize this.
Ann: SNT to Trial New Cancer Indication Following MRFF Grant, page-3
Add to My Watchlist
What is My Watchlist?
